Get the Stockscreener App
1.50
0.00%
0.00
Skye Bioscience Inc stock is traded at $1.50, with a volume of 205.10K.
It is up +0.00% in the last 24 hours and down -68.42% over the past month.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
See More
Previous Close:
$1.50
Open:
$1.47
24h Volume:
205.10K
Relative Volume:
0.26
Market Cap:
$44.62M
Revenue:
-
Net Income/Loss:
$-42.37M
P/E Ratio:
-1.4037
EPS:
-1.0686
Net Cash Flow:
$-34.94M
1W Performance:
-3.85%
1M Performance:
-68.42%
6M Performance:
-33.04%
1Y Performance:
-72.43%
1-Day Range:
$1.43
$1.51
1-Week Range:
$1.43
$1.63
52-Week Range:
$1.14
$5.96
Skye Bioscience Inc Stock (SKYE) Company Profile
Name
Skye Bioscience Inc
Sector
Industry
Phone
(858) 410-0266
Address
11250 EL CAMINO REAL, SUITE 100, SAN DIEGO
Compare SKYE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SKYE
Skye Bioscience Inc.
|
3.10 | 12.89M | 0 | 0 | 0 | 0.00 |
|
MOBBW
Mobilicom Limited Warrants
|
2.50 | 4.21B | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
20.00 | 372.90M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
4.82 | 217.47M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.2265 | 502.27M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
DAVEW
Dave Inc
|
1.4399 | 0 | 0 | 0 | 0 | 0.00 |
Skye Bioscience Inc Stock (SKYE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-06-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Oct-06-25 | Downgrade | Craig Hallum | Buy → Hold |
| Aug-15-25 | Initiated | Evercore ISI | Outperform |
| Feb-28-25 | Initiated | William Blair | Outperform |
| Sep-30-24 | Initiated | Scotiabank | Sector Outperform |
| Sep-10-24 | Initiated | JMP Securities | Mkt Outperform |
| Jul-09-24 | Initiated | Craig Hallum | Buy |
| May-23-24 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-12-24 | Initiated | Oppenheimer | Outperform |
View All
Skye Bioscience Inc Stock (SKYE) Latest News
Published on: 2025-11-04 06:12:12 - newser.com
Intraday pattern recognizer results for Skye Bioscience Inc.Earnings Recap Report & Daily Oversold Stock Bounce Ideas - newser.com
Will Skye Bioscience Inc. (09R) stock announce a stock split2025 Volatility Report & Safe Entry Momentum Tips - newser.com
Price action breakdown for Skye Bioscience Inc.GDP Growth & Weekly High Conviction Trade Ideas - newser.com
Live market analysis of Skye Bioscience Inc.Weekly Profit Summary & Weekly High Conviction Trade Ideas - newser.com
Is Skye Bioscience Inc. (09R) stock a momentum leaderJuly 2025 Sector Moves & AI Enhanced Trading Alerts - newser.com
Is Skye Bioscience Inc. stock a defensive play in 2025Weekly Risk Report & Growth-Oriented Investment Plans - newser.com
How to integrate Skye Bioscience Inc. into portfolio analysis toolsProfit Target & AI Enhanced Trading Alerts - newser.com
Applying big data sentiment scoring on Skye Bioscience Inc.July 2025 Patterns & Weekly Top Gainers Trade List - newser.com
Will Skye Bioscience Inc. (09R) stock outperform foreign stocksJuly 2025 Opening Moves & Weekly Momentum Stock Picks - newser.com
Will Skye Bioscience Inc. stock go up soon2025 Geopolitical Influence & Expert-Curated Trade Recommendations - newser.com
Why Skye Bioscience Inc. stock appeals to dividend seekersQuarterly Earnings Report & Expert Curated Trade Ideas - newser.com
Skye Bioscience Inc expected to post a loss of 31 cents a shareEarnings Preview - TradingView
Is Skye Bioscience Inc. forming a reversal patternInsider Selling & Weekly Return Optimization Plans - newser.com
Is Skye Bioscience Inc. still worth holding after the dipJuly 2025 Setups & Daily Stock Trend Watchlist - newser.com
Volatility clustering patterns for Skye Bioscience Inc.Trade Exit Report & Safe Entry Zone Identification - newser.com
How Skye Bioscience Inc. stock reacts to inflationary pressuresMarket Weekly Review & Momentum Based Trading Ideas - newser.com
Can Skye Bioscience Inc. stock maintain growth trajectoryBuy Signal & Fast Exit/Entry Strategy Plans - newser.com
What technical models suggest about Skye Bioscience Inc.’s comeback - newser.com
How Skye Bioscience Inc. stock performs in weak economyFed Meeting & Daily Growth Stock Tips - newser.com
Will Skye Bioscience Inc. (09R) stock keep raising dividendsJuly 2025 EndofMonth & Community Consensus Stock Picks - newser.com
Is Skye Bioscience Inc a good long term investmentCapital Gains Strategies & Rapid Portfolio Investment - earlytimes.in
Regression analysis insights on Skye Bioscience Inc. performanceGDP Growth & Weekly Market Pulse Alerts - newser.com
What analysts say about Skye Bioscience Inc stockSupport Zone Identification & Ride the Trends That Billionaires Follow - earlytimes.in
Will Skye Bioscience Inc. stock deliver consistent dividendsGold Moves & Fast Exit and Entry Strategy Plans - newser.com
Skye Bioscience Inc Stock (SKYE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Skye Bioscience Inc Stock (SKYE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Schwab Andrew J. | Director |
Aug 21 '25 |
Sale |
3.57 |
60,956 |
217,613 |
63,963 |
| 5AM Partners VII, LLC | 10% Owner |
Aug 22 '25 |
Sale |
3.42 |
170,449 |
582,936 |
57,493 |
| 5AM Partners VII, LLC | 10% Owner |
Aug 21 '25 |
Sale |
3.57 |
60,956 |
217,613 |
63,963 |
| Diep Tuan Tu | Chief Development Officer |
Nov 18 '24 |
Sale |
4.99 |
19,489 |
97,250 |
82,259 |
| Diep Tuan Tu | Chief Development Officer |
Nov 15 '24 |
Sale |
5.55 |
85 |
472 |
101,748 |
| ARSENAULT KAITLYN | Chief Financial Officer |
Nov 18 '24 |
Sale |
4.99 |
43,206 |
215,598 |
166,342 |
| ARSENAULT KAITLYN | Chief Financial Officer |
Nov 15 '24 |
Sale |
5.55 |
190 |
1,054 |
209,548 |
| DHILLON PUNIT | Chief Executive Officer |
Nov 18 '24 |
Sale |
4.99 |
82,546 |
411,905 |
329,823 |
| DHILLON PUNIT | Chief Executive Officer |
Nov 15 '24 |
Sale |
5.55 |
364 |
2,020 |
412,369 |
| Grayson Paul A. | Director |
Nov 18 '24 |
Sale |
4.99 |
86,244 |
430,358 |
259,701 |
1.24%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):